Latest stories on CCCC
C4 Therapeutics, Inc. (CCCC) files 8-K
SEC 8-K50 · neutralgeneral
C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts
Seeking Alpha56 · neutralproduct/pr
C4 Therapeutics, Inc. (CCCC) files 8-K
SEC 8-K50 · neutralgeneral
C4 Therapeutics GAAP EPS of -$0.18 beats by $0.05, revenue of $6.64M beats by $2.64M
Seeking Alpha63 · neutralearnings
C4 Therapeutics, Inc. (CCCC) files 8-K
SEC 8-K50 · neutralgeneral
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress
TipRanks63 · neutralproduct/pr
C4 Therapeutics, Inc. (CCCC) files 8-K
SEC 8-K50 · neutralgeneral
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
Seeking Alpha63 · neutralanalyst
Bristol-Myers multiple myeloma data boosts C4
Seeking Alpha67 · bullishproduct/pr